Free Trial
NASDAQ:DERM

Journey Medical Q1 2026 Earnings Report

Journey Medical logo
$5.15 -0.03 (-0.58%)
As of 09:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Journey Medical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.07
Beat/Miss
N/A
One Year Ago EPS
N/A

Journey Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$15.47 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Journey Medical Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Journey Medical Earnings Headlines

Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.tc pixel
See More Journey Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Journey Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Journey Medical and other key companies, straight to your email.

About Journey Medical

Journey Medical (NASDAQ:DERM) Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles. Journey Medical leverages an in-house commercial infrastructure, including a specialized sales force and key partnerships with pharmacies and distributors, to reach dermatology practices and healthcare providers nationwide.

Underpinning its growth strategy is an acquisition-driven approach that targets established, off-patent dermatology assets with stable prescription demand. The company’s management team, comprised of executives with deep experience in pharmaceutical marketing and specialty drug launches, continues to screen for complementary assets to expand its addressable market and enhance shareholder value.

View Journey Medical Profile